MAM
Mindshare expands Emerging Markets Group under Ashutosh Srivastava
MUMBAI: Mindshare chairman Asia and CEO Emerging Markets Group Ashutosh Srivastava has now been given the added responsibility of the Middle East and Africa.
The change comes as Helen McRae is appointed Mindshare UK CEO, a role she will combine with her responsibility as chair of Mindshare Western Europe, representing Europe on the GroupM Europe board. McRae’s Africa responsibilities will now pass to Srivastava, whose extended remit will cover APAC, Russia, the Middle East and Africa.
Mindshare global CEO Nick Emery said, “Ashutosh continues to broaden his scope and influence as all our best people do. I’m delighted that his influence will now have a direct effect on Asia, Africa and the Middle East. We will be all the richer for it.”
Srivastava added, “The intent of this is to more strongly connect the growth markets together in the same way that many of our clients have organised themselves and so helping them unlock that growth through a strong, joined up network of resources.”
At the same time, Christof Baron will take on the role CEO of Central and Eastern Europe (CEE) to drive Mindshare growth in the region and oversee the international development of German based clients. Baron will also continue his role as non-executive chairman of Mindshare Germany.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
